XOMA Corp  

(Public, NASDAQ:XOMA)   Watch this stock  
Find more results for XOMA
0.553
-0.007 (-1.21%)
Jul 22 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 0.54 - 0.58
52 week 0.44 - 2.03
Open 0.57
Vol / Avg. 0.00/1.48M
Mkt cap 66.58M
P/E     -
Div/yield     -
EPS -0.06
Shares 120.37M
Beta 2.57
Inst. own 23%
Aug 4, 2016
Q2 2016 XOMA Corp Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Jul 12, 2016
XOMA Corp at Cantor Fitzgerald Healthcare Conference - Webcast
Jun 9, 2016
XOMA Corp at Jefferies Healthcare Conference - Webcast
May 20, 2016
XOMA Corp Annual Shareholders Meeting (Estimated)
May 19, 2016
XOMA Corp Annual Shareholders Meeting
May 4, 2016
Q1 2016 XOMA Corp Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '16) 2015
Net profit margin -211.13% -37.16%
Operating margin -353.08% -71.64%
EBITD margin - -62.21%
Return on average assets -52.64% -25.09%
Return on average equity - -5216.71%
Employees 80 -
CDP Score - -

Address

2910 7th St
BERKELEY, CA 94710-2700
United States - Map
+1-510-6441170 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

XOMA Corporation is a development-stage biotechnology company. The Company focuses on the discovery and development of monoclonal antibody-based therapeutics. It has five products in its endocrine portfolio, two of which are developed as part of its XOMA Metabolism (XMet) platform. Its products include XOMA 358, XOMA 129, XOMA 213 and Gevokizumab. Its XOMA 358 is meant for long-acting treatment of hyperinsulinemic hypoglycemia. XOMA 129 is meant for rapid onset, short-acting treatment of severe acute hypoglycemia. XOMA 213 is a Phase II-ready product candidate targeting the prolactin receptor, as well as research-stage programs targeting the parathyroid receptor (PTH1R) and the adrenal corticotropic hormone (ACTH). Gevokizumab is a humanized monoclonal antibody with allosteric properties that has the potential to treat patients with a range of inflammatory diseases. Its technologies include Antibody Discovery Advanced Platform Technologies (ADAPT), ModulX and OptimX.

Officers and directors

W. Denman Van Ness Lead Independent Chairman of the Board
Age: 72
Bio & Compensation  - Reuters
John W. Varian Chief Executive Officer, Director
Age: 55
Bio & Compensation  - Reuters
Thomas M. Burns Chief Financial Officer
Bio & Compensation  - Reuters
James R. Neal Chief Operating Officer, Senior Vice President
Age: 56
Bio & Compensation  - Reuters
Patrick J. Scannon M.D., Ph.D. Executive Vice President, Chief Scientific Officer, Director
Age: 67
Bio & Compensation  - Reuters
Paul D. Rubin M.D. Senior Vice President - Research and Development, Chief Medical Officer
Age: 61
Bio & Compensation  - Reuters
Thomas Klein Vice President, Chief Commercial Officer
Age: 53
Bio & Compensation  - Reuters
William K. Bowes Jr. Independent Director
Age: 88
Bio & Compensation  - Reuters
Peter Barton Hutt Independent Director
Age: 81
Bio & Compensation  - Reuters
Joseph M. Limber Independent Director
Age: 62
Bio & Compensation  - Reuters